参考文献/References:
[1] Truby LK,Rogers JG. Advanced heart failure:epidemiology,diagnosis,and therapeutic approaches[J]. JACC Heart Fail,2020,8(7):523-536.
[2] McMurray JJV,Solomon SD,Inzucchi SE,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21):1995-2008.
[3] Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657.
[4] Solomon SD,McMurray JJV,Anand IS,et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction[J]. N Engl J Med,2019,381(17):1609-1620.
[5] McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[6] Ludue?a RF. A hypothesis on the origin and evolution of tubulin[J]. Int Rev Cell Mol Biol,2013,302:41-185.
[7] Goodson HV,Jonasson EM. Microtubules and microtubule-associated proteins[J]. Cold Spring Harb Perspect Biol,2018,10(6):a022608.
[8] Desai A,Mitchison TJ. Microtubule polymerization dynamics[J]. Annu Rev Cell Dev Biol,1997,13:83-117.
[9] Janke C,Magiera MM. The tubulin code and its role in controlling microtubule properties and functions[J]. Nat Rev Mol Cell Biol,2020,21(6):307-326.
[10] Zile MR,Green GR,Schuyler GT,et al. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy[J]. J Am Coll Cardiol,2001,37(4):1080-1084.
[11] Chen CY,Caporizzo MA,Bedi K,et al. Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure[J]. Nat Med,2018,24(8):1225-1233.
[12] Wang X,Li F,Campbell SE,et al. Chronic pressure overload cardiac hypertrophy and failure in guinea pigs:Ⅱ. Cytoskeletal remodeling[J]. J Mol Cell Cardiol,1999,31(2):319-331.
[13] Ishibashi Y,Takahashi M,Isomatsu Y,et al. Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes[J]. Am J Physiol Heart Circ Physiol,2003,285(3):H1270-H1285.
[14] Yuan Q,Zhan L,Zhou QY,et al. SIRT2 regulates microtubule stabilization in diabetic cardiomyopathy[J]. Eur J Pharmacol,2015,764:554-561.
[15] Ng DC,Ng IH,Yeap YY,et al. Opposing actions of extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) in regulating microtubule stabilization during cardiac hypertrophy[J]. J Biol Chem,2011,286(2):1576-1587.
[16] Cheng G,Zile MR,Takahashi M,et al. A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart[J]. Am J Physiol Heart Circ Physiol,2008,294(5):H2231-H2241.
[17] Fassett JT,Xu X,Hu X,et al. Adenosine regulation of microtubule dynamics in cardiac hypertrophy[J]. Am J Physiol Heart Circ Physiol,2009,297(2):H523-H532.
[18] Zhang C,Chen B,Guo A,et al. Microtubule-mediated defects in junctophilin-2 trafficking contribute to myocyte transverse-tubule remodeling and Ca2+ handling dysfunction in heart failure[J]. Circulation ,2014,129(17):1742-1750.
[19] Fassett J,Xu X,Kwak D,et al. Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction[J]. J Mol Cell Cardiol,2019,130:49-58.
[20] Xiao J,Zhao H,Liang D,et al. Taxol,a microtubule stabilizer,improves cardiac contractile function during ischemia in vitro[J]. Pharmacology,2010,85(5):301-310.
[21] Xiao J,Liang D,Liu Y,et al. Taxol,a microtubule stabilizer,improves cardiac functional recovery during postischemic reperfusion in rat in vitro[J]. Cardiovasc Ther,2012,30(1):12-30.
[22] Perez EA. Paclitaxel and cardiotoxicity[J]. J Clin Oncol,1998,16(11):3481-3482.
[23] Belmadani S,Poüs C,Fischmeister R,et al. Post-translational modifications of tubulin and microtubule stability in adult rat ventricular myocytes and immortalized HL-1 cardiomyocytes[J]. Mol Cell Biochem,2004,258(1-2):35-48.
[24] Schuldt M,Pei J,Harakalova M,et al. Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy[J]. Circ Heart Fail,2021,14(1):e007022.
[25] Robison P,Caporizzo MA,Ahmadzadeh H,et al. Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes[J]. Science,2016,352(6284):aaf0659.
[26] Nieuwenhuis J,Brummelkamp TR. The tubulin detyrosination cycle:function and enzymes[J]. Trends Cell Biol,2019,29(1):80-92.
[27] Nieuwenhuis J,Adamopoulos A,Bleijerveld OB,et al. Vasohibins encode tubulin detyrosinating activity[J]. Science,2017,358(6369):1453-1456.
[28] Aillaud C,Bosc C,Peris L,et al. Vasohibins/SVBP are tubulin carboxypeptidases (TCPs) that regulate neuron differentiation[J]. Science,2017,358(6369):1448-1453.
[29] Wang N,Bosc C,Ryul Choi S,et al. Structural basis of tubulin detyrosination by the vasohibin—SVBP enzyme complex[J]. Nat Struct Mol Biol,2019,26(7):571-582.
[30] Li F,Hu Y,Qi S,et al. Structural basis of tubulin detyrosination by vasohibins[J]. Nat Struct Mol Biol,2019,26(7):583-591.
[31] Iqbal Z,Tawamie H,Ba W,et al. Loss of function of SVBP leads to autosomal recessive intellectual disability,microcephaly,ataxia,and hypotonia[J]. Genet Med,2019,21(8):1790-1796.
[32] Chen CY,Salomon AK,Caporizzo MA,et al. Depletion of vasohibin 1 speeds contraction and relaxation in failing human cardiomyocytes[J]. Circ Res,2020,127(2):e14-e27.
[33] Tian J,Shan XL,Wang SN,et al. Trans-cinnamaldehyde suppresses microtubule detyrosination and alleviates cardiac hypertrophy[J]. Eur J Pharmacol,2022,914:174687.
[34] Rankin JS,Arentzen CE,McHale PA,et al. Viscoelastic properties of the diastolic left ventricle in the conscious dog[J]. Circ Res,1977,41(1):37-45.
[35] Hess OM,Grimm J,Krayenbuehl HP. Diastolic simple elastic and viscoelastic properties of the left ventricle in man[J]. Circulation,1979,59(6):1178-1187.
[36] Fraites TJ Jr,Saeki A,Kass DA. Effect of altering filling pattern on diastolic pressure-volume curve[J]. Circulation,1997,96(12):4408-4414.
[37] Caporizzo MA,Chen CY,Bedi K,et al. Microtubules increase diastolic stiffness in failing human cardiomyocytes and myocardium[J]. Circulation,2020,141(11):902-915.
[38] Doerflinger H,Benton R,Shulman JM,et al. The role of PAR-1 in regulating the polarised microtubule cytoskeleton in the Drosophila follicular epithelium[J]. Development,2003,130(17):3965-3975.
[39] Goldstein B,Macara IG. The PAR proteins:fundamental players in animal cell polarization[J]. Dev Cell,2007,13(5):609-622.
[40] Trinczek B,Brajenovic M,Ebneth A,et al. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes[J]. J Biol Chem,2004,279(7):5915-5923.
[41] Yu X,Chen X,Amrute-Nayak M,et al. MARK4 controls ischaemic heart failure through microtubule detyrosination[J]. Nature,2021,594(7864):560-565.